Views & Analysis What doctors say about EpiPen pricing The furore over Mylan’s ‘price gouging’ in relation to EpiPen in the US went global, thanks to social media.
News Mylan responds to price backlash with generic EpiPen Company launches cut-price generic alongside existing branded version
News Mylan and Biocon file Herceptin biosimilar in Europe First Herceptin biosimilar filed in EU, companies say.
News Clinton attacks Mylan over drug pricing Presidential hopeful criticises "outrageous" EpiPen price increase.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.